Sun Pharma Funds $2.5 Million Dermatology Professorship
The pharmaceutical company is embedding influence in Mount Sinai's research program to shape future dermatology standards.
Updated on Oct. 24, 2026 in Healthcare

Live Poll
Do you trust that corporate-funded professorships prioritize patient care over the interests of the donor?
Sun Pharma has established a $2.5 million endowed professorship at the Icahn School of Medicine at Mount Sinai in New York. The program aims to advance dermatology research and clinical training within the Kimberly and Eric J. Waldman Department of Dermatology.
Why it matters
Endowed professorships provide long-term academic funding that helps pharmaceutical companies influence future clinical standards and research priorities. By aligning with Mount Sinai, Sun Pharma secures a strategic foothold in a top-tier research institution.
The new dermatology professorship is backed by a $2.5 million endowment, marking a significant investment in academic leadership. Sun Pharma currently supplies medicines to 100 countries and ranks as the second-largest pharmaceutical dermatology firm in the U.S. by prescription volume.
The players
Sun Pharma
A global pharmaceutical company headquartered in India that ranks as the second-largest dermatology drug provider in the U.S.
Icahn School of Medicine at Mount Sinai
A prominent New York-based academic medical center recognized for advanced clinical training and research.
Mark G. Lebwohl
The Dean for Clinical Therapeutics at Mount Sinai and former president of the American Academy of Dermatology.
The details
The endowment functions by generating long-term capital for academic leadership within the Kimberly and Eric J. Waldman Department of Dermatology. This funding supports the translation of scientific discoveries into clinical treatments while preparing the next generation of dermatology specialists. Mark G. Lebwohl, the current Dean for Clinical Therapeutics at the medical school, will hold the inaugural position.
Timeline
October 24, 2026: Official report on the professorship establishment.
2015 to 2016: Dr. Mark G. Lebwohl served as American Academy of Dermatology President.
Market Landscape
This move deepens the long-standing relationship between major pharmaceutical manufacturers and academic research hubs like the Icahn School of Medicine at Mount Sinai. It follows a broader industry pattern where companies trade capital for influence in specialized clinical departments.
Operators in the healthcare space should monitor how this endowment impacts the clinical research agenda at Mount Sinai. Firms in competitive dermatology sectors should evaluate whether their academic footprint aligns with their current product pipeline.
The takeaway
Pharmaceutical companies continue to use endowed chairs as a mechanism to secure research output and influence training in critical sub-specialties. Operators should track the research findings published by this new office to anticipate shifts in clinical standards for dermatological therapeutics.
Further reading
Explore industry trends in Healthcare to understand how academic partnerships impact medical research and market leadership.
Source note: This article includes information reported by Themachinemaker.
Live Poll
Do you trust that corporate-funded professorships prioritize patient care over the interests of the donor?





